CN115011623A - Recombinant engineering bacterium and construction method and application thereof - Google Patents
Recombinant engineering bacterium and construction method and application thereof Download PDFInfo
- Publication number
- CN115011623A CN115011623A CN202111084984.2A CN202111084984A CN115011623A CN 115011623 A CN115011623 A CN 115011623A CN 202111084984 A CN202111084984 A CN 202111084984A CN 115011623 A CN115011623 A CN 115011623A
- Authority
- CN
- China
- Prior art keywords
- pantolactone
- recombinant
- recombinant vector
- seq
- dehydrogenase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 58
- 238000010276 construction Methods 0.000 title claims abstract description 12
- 101710088194 Dehydrogenase Proteins 0.000 claims abstract description 51
- SERHXTVXHNVDKA-SCSAIBSYSA-N (3s)-3-hydroxy-4,4-dimethyloxolan-2-one Chemical compound CC1(C)COC(=O)[C@H]1O SERHXTVXHNVDKA-SCSAIBSYSA-N 0.000 claims abstract description 46
- 238000006243 chemical reaction Methods 0.000 claims abstract description 40
- SERHXTVXHNVDKA-BYPYZUCNSA-N (R)-pantolactone Chemical compound CC1(C)COC(=O)[C@@H]1O SERHXTVXHNVDKA-BYPYZUCNSA-N 0.000 claims abstract description 30
- HRTOQFBQOFIFEE-UHFFFAOYSA-N 2-dehydropantolactone Chemical compound CC1(C)COC(=O)C1=O HRTOQFBQOFIFEE-UHFFFAOYSA-N 0.000 claims abstract description 21
- SERHXTVXHNVDKA-UHFFFAOYSA-N pantolactone Chemical compound CC1(C)COC(=O)C1O SERHXTVXHNVDKA-UHFFFAOYSA-N 0.000 claims abstract description 14
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 claims abstract description 7
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 155
- 239000013598 vector Substances 0.000 claims description 117
- -1 D-pantoic acid lactone Chemical class 0.000 claims description 71
- 239000002773 nucleotide Substances 0.000 claims description 52
- 125000003729 nucleotide group Chemical group 0.000 claims description 52
- 108090000854 Oxidoreductases Proteins 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 31
- 239000001963 growth medium Substances 0.000 claims description 24
- 238000012258 culturing Methods 0.000 claims description 8
- 238000011081 inoculation Methods 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 4
- OTOIIPJYVQJATP-BYPYZUCNSA-M (R)-pantoate Chemical compound OCC(C)(C)[C@@H](O)C([O-])=O OTOIIPJYVQJATP-BYPYZUCNSA-M 0.000 claims description 3
- 241001052560 Thallis Species 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000008055 phosphate buffer solution Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 2
- 108010070495 2-dehydropantoate 2-reductase Proteins 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 abstract description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 108090000604 Hydrolases Proteins 0.000 description 29
- 102000004157 Hydrolases Human genes 0.000 description 27
- 239000000047 product Substances 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 22
- 241000588724 Escherichia coli Species 0.000 description 20
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 229930027917 kanamycin Natural products 0.000 description 16
- 229960000318 kanamycin Drugs 0.000 description 16
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 16
- 229930182823 kanamycin A Natural products 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 239000012137 tryptone Substances 0.000 description 16
- 229960000723 ampicillin Drugs 0.000 description 15
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 108020004705 Codon Proteins 0.000 description 14
- 238000005457 optimization Methods 0.000 description 14
- 238000005520 cutting process Methods 0.000 description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 108700010070 Codon Usage Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000001976 enzyme digestion Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- OTOIIPJYVQJATP-BYPYZUCNSA-N (R)-pantoic acid Chemical compound OCC(C)(C)[C@@H](O)C(O)=O OTOIIPJYVQJATP-BYPYZUCNSA-N 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 102000012410 DNA Ligases Human genes 0.000 description 5
- 108010061982 DNA Ligases Proteins 0.000 description 5
- 241000233732 Fusarium verticillioides Species 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- 230000001131 transforming effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001728 nano-filtration Methods 0.000 description 4
- 238000012257 pre-denaturation Methods 0.000 description 4
- 230000006340 racemization Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 241000186361 Actinobacteria <class> Species 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000186226 Corynebacterium glutamicum Species 0.000 description 2
- 239000011703 D-panthenol Substances 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 235000004866 D-panthenol Nutrition 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- 241000427940 Fusarium solani Species 0.000 description 2
- 241001390778 Humibacter Species 0.000 description 2
- 241000187708 Micromonospora Species 0.000 description 2
- 241000187654 Nocardia Species 0.000 description 2
- 241000520272 Pantoea Species 0.000 description 2
- 241000588696 Pantoea ananatis Species 0.000 description 2
- 241000187561 Rhodococcus erythropolis Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229960003949 dexpanthenol Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N pantothenic acid Chemical compound OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- OTOIIPJYVQJATP-SCSAIBSYSA-N (2s)-2,4-dihydroxy-3,3-dimethylbutanoic acid Chemical compound OCC(C)(C)[C@H](O)C(O)=O OTOIIPJYVQJATP-SCSAIBSYSA-N 0.000 description 1
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000222292 [Candida] magnoliae Species 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007273 lactonization reaction Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000002910 solid waste Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01168—2-Dehydropantolactone reductase (A-specific) (1.1.1.168)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01169—2-Dehydropantoate 2-reductase (1.1.1.169), i.e. ketopantoate-reductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01002—Formate dehydrogenase (1.2.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a recombinant engineering bacterium, a construction method and application thereof, wherein the recombinant engineering bacterium is induced to efficiently express L-pantolactone dehydrogenase, ketopantolactone reductase and D-pantolactone hydrolase, and after NADPH is added, DL-pantolactone is efficiently converted to generate the D-pantolactone. The recombinant engineering bacterium provided by the invention improves the selectivity of L-pantolactone dehydrogenase, obviously improves the purity and quality of D-pantolactone, reaction efficiency and resource utilization rate, and has the advantages of simplicity and convenience in operation, environmental friendliness, higher cost and the like.
Description
Technical Field
The invention relates to the technical field of genetic engineering, in particular to a recombinant engineering bacterium, a construction method and application thereof.
Background
D-pantoic acid lactone is a medical intermediate for synthesizing vitamin medicine D-panthenol and neurotrophic medicine D-calcium homopantothenate, is used as a synthetic precursor of feed additives and daily chemical products, and has annual output of more than ten thousand tons.
DL-pantoic acid lactone is usually prepared by a chemical synthesis method, and the prepared DL-pantoic acid lactone is converted into D-pantoic acid lactone by resolution. The method for obtaining the D-pantolactone by resolving the DL-pantolactone by a microbial enzyme method comprises the following steps: 1) d-pantoic acid lactone or L-pantoic acid lactone in the DL-pantoic acid lactone is selectively hydrolyzed by microbial enzyme to obtain the L-pantoic acid lactone and the D-pantoic acid or the L-pantoic acid and the D-pantoic acid lactone; 2) extracting the mixed solution by using an organic reagent to realize the separation of L-pantolactone and D-pantoic acid; 3) d-pantoic acid is subjected to lactonization to obtain D-pantoic acid lactone, and L-pantoic acid lactone is subjected to chemical racemization to be changed into DL-pantoic acid lactone again and then is split. This method has the following drawbacks: firstly, the separation steps are multiple, and the separation efficiency is low; secondly, a great amount of pigment and other impurities are generated in the chemical racemization process, and the D-pantoic acid lactone prepared by splitting has darker color and poorer appearance quality; thirdly, chemical racemization can generate a large amount of sulfate, form solid waste and cause environmental pollution.
CN110423717A discloses a multienzyme recombinant cell and a method for synthesizing D-pantolactone by multienzyme cascade catalysis, wherein the method comprises the step of converting DL-pantolactone into the ketopantolactone and further generating the D-pantolactone by expressing L-pantolactone dehydrogenase, ketopantolactone reductase and glucose dehydrogenase through the recombinant cell. The method has the following defects: the L-pantolactone dehydrogenase has poor selectivity on L-pantolactone and catalytic reaction thereof, and can catalyze the L-pantolactone to generate ketopantolactone and D-pantolactone to generate ketopantolactone, the L-pantolactone and the D-pantolactone compete and combine with an active site of the L-pantolactone dehydrogenase at the same time, and the D-pantolactone is involved in a cyclic reaction, so that the enzyme activity is reduced; when the content of L-pantolactone in a substrate is low, the L-pantolactone dehydrogenase cannot be effectively contacted with the L-pantolactone dehydrogenase, and complete conversion is difficult, so that the product prepared by the method contains L-pantolactone, the purification difficulty is increased, and the product quality is difficult to ensure.
Therefore, how to develop a recombinant vector and engineering bacteria thereof which have high selectivity and are beneficial to improving the purity and quality of D-pantoic acid lactone, the reaction efficiency, the resource utilization rate and the like becomes an aspect which needs to be solved urgently in the field.
Disclosure of Invention
The invention aims to provide a recombinant vector which contains a recombinant vector, wherein the nucleotide sequence of an L-pantolactone dehydrogenase encoding gene is shown as SEQ ID No.1, the nucleotide sequence of a ketopantolactone reductase encoding gene is shown as SEQ ID No.2, and the nucleotide sequence of a D-pantolactone hydrolase encoding gene is shown as SEQ ID No. 3.
In the preferred technical scheme of the invention, the nucleotide sequence of the coding gene of L-pantolactone dehydrogenase is shown as SEQ ID NO.1, the nucleotide sequence of the coding gene of ketopantolactone reductase is shown as SEQ ID NO.2, and the nucleotide sequence of the coding gene of D-pantolactone hydrolase is shown as SEQ ID NO.3 on the first recombinant vector, the second recombinant vector and the third recombinant vector respectively.
In a preferred embodiment of the present invention, the recombinant vector optionally comprises any one of a fourth recombinant vector or a fifth recombinant vector, wherein the fourth recombinant vector comprises a nucleotide sequence of an L-pantoate lactone dehydrogenase-encoding gene shown in SEQ ID No.1 and a nucleotide sequence of a ketopantoate lactone reductase-encoding gene shown in SEQ ID No.2, the fifth recombinant vector comprises a nucleotide sequence of an L-pantoate lactone dehydrogenase-encoding gene shown in SEQ ID No.1, a nucleotide sequence of a ketopantoate lactone reductase-encoding gene shown in SEQ ID No.2 and a nucleotide sequence of a D-pantoate lactone hydrolase-encoding gene shown in SEQ ID No. 3.
In a preferred technical scheme of the invention, the recombinant vector is selected from a fourth recombinant vector which comprises a nucleotide sequence of an L-pantoate lactone dehydrogenase encoding gene shown in SEQ ID No.1 and a nucleotide sequence of a ketopantoate lactone reductase encoding gene shown in SEQ ID No. 2.
In a preferred technical scheme of the invention, the recombinant vector further comprises a third recombinant vector D-pantolactone hydrolase coding gene, and the nucleotide sequence of the D-pantolactone hydrolase coding gene is shown in SEQ ID NO. 3.
In the preferable technical scheme of the invention, the recombinant vector is used for preparing D-pantolactone from DL-pantolactone.
In a preferred technical scheme of the invention, the coding gene of the L-pantoate lactone dehydrogenase is derived from any one of rhodococcus erythropolis, mycobacterium, nocardia, streptomycete and actinomycetes.
In the preferred technical scheme of the invention, the L-pantolactone dehydrogenase coding gene is subjected to codon optimization and enzyme cutting sites to obtain an L-pantolactone dehydrogenase gene sequence.
In a preferred embodiment of the present invention, the cleavage site is selected from any one of XhoI and NdeI or a combination thereof.
In the preferred technical scheme of the invention, the L-pantoate lactone dehydrogenase gene sequence is artificially synthesized to prepare a target gene 1, and the nucleotide sequence of the target gene 1 is shown as SEQ ID NO. 1.
In a preferred technical scheme of the invention, the ketopantoate lactone reductase coding gene is derived from any one of candida magnoliae, micromonospora and streptomyces.
In the preferred technical scheme of the invention, the ketopantoate lactone reductase coding gene is subjected to codon optimization and enzyme cutting sites to obtain a ketopantoate lactone reductase gene sequence.
In a preferred embodiment of the present invention, the cleavage site is selected from one of SacI and NotI, or a combination thereof.
In the preferred technical scheme of the invention, the ketopantoate lactone reductase gene sequence is artificially synthesized to prepare a target gene 2, and the nucleotide sequence of the target gene 2 is shown as SEQ ID NO. 2.
In a preferred technical scheme of the invention, the D-pantoate lactone hydrolase coding gene is derived from any one of fusarium moniliforme, fusarium solani and fusarium.
In the preferred technical scheme of the invention, the D-pantoic lactone hydrolase coding gene is subjected to codon optimization and enzyme cutting sites to obtain a D-pantoic lactone gene sequence.
In a preferred embodiment of the present invention, the cleavage site is selected from any one of XhoI and NdeI or a combination thereof.
In the preferable technical scheme of the invention, the D-pantolactone hydrolase gene sequence is artificially synthesized to prepare the target gene 3, and the nucleotide sequence of the target gene 3 is shown in SEQ ID NO. 3.
In a preferred embodiment of the present invention, the codon optimization is performed according to the codon preference of E.coli.
In a preferred embodiment of the present invention, the vector for recombination is selected from any one of pET-21a plasmid, pET-28a plasmid, pRSFDuet-I plasmid, or a combination thereof.
In a preferred embodiment of the present invention, the method for obtaining the first recombinant vector comprises the following steps: encoding a gene of L-pantolactone dehydrogenase or a target gene 1 or a gene shown as SEQ ID NO: 1 into a first vector to obtain a first recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the second recombinant vector comprises the following steps: the ketopantoate lactone reductase coding gene or the target gene 2 or the gene shown as SEQ ID NO: 2 into a second vector to obtain a second recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the third recombinant vector comprises the following steps: d-pantoic acid lactone hydrolase coding gene or target gene 3 or a gene shown as SEQ ID NO: 3 into a third vector to obtain a third recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fourth recombinant vector comprises the following steps: encoding a gene of L-pantolactone dehydrogenase or a target gene 1 or a gene shown as SEQ ID NO: 1 and ketopantoate lactone reductase coding gene or target gene 2 or a nucleotide sequence shown as SEQ ID NO: 2 into a fourth vector to obtain a fourth recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fourth recombinant vector comprises the following steps: firstly, encoding gene or target gene 1 of L-pantoate lactone dehydrogenase or a gene shown as SEQ ID NO: 1 into a fourth vector, and then cloning a ketopantoate lactone reductase coding gene or a target gene 2 or a nucleotide sequence shown as SEQ ID NO: 2 into a fourth vector to obtain a fourth recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fourth recombinant vector comprises the following steps: firstly, a ketopantoate lactone reductase coding gene or a target gene 2 or a gene shown as SEQ ID NO: 2 into a fourth vector, and then cloning the L-pantolactone dehydrogenase coding gene or the target gene 1 or a nucleotide sequence shown as SEQ ID NO: 1 into a fourth vector to obtain a fourth recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fifth recombinant vector comprises the following steps: encoding a gene of L-pantolactone dehydrogenase or a target gene 1 or a gene shown as SEQ ID NO: 1, ketopantoate lactone reductase coding gene or target gene 2 or a nucleotide sequence shown as SEQ ID NO: 2, D-pantolactone hydrolase coding gene or target gene 3 or the nucleotide sequence shown as SEQ ID NO: 3 into a fifth vector to obtain a fifth recombinant vector, wherein the cloning sequence of the 3 genes or the nucleotide sequences is not shown in sequence.
Another objective of the invention is to provide a recombinant engineering bacterium, which comprises any one or combination of a first recombinant vector capable of expressing L-pantolactone dehydrogenase, a second recombinant vector expressing ketopantolactone reductase and a third recombinant vector expressing D-pantolactone hydrolase;
and/or the recombinant engineering bacteria comprise a fourth recombinant vector capable of co-expressing L-pantolactone dehydrogenase and ketopantolactone reductase;
and/or the recombinant engineering bacteria comprise a fifth recombinant vector capable of co-expressing L-pantolactone dehydrogenase, ketopantolactone reductase and D-pantolactone hydrolase.
In a preferred technical scheme of the invention, the recombinant engineering bacteria comprise a fourth recombinant vector capable of co-expressing L-pantoate lactone dehydrogenase and ketopantoate lactone reductase.
In a preferred technical scheme of the invention, the recombinant engineering bacteria also comprise a third recombinant vector for expressing D-pantolactone hydrolase, or are combined with a second recombinant engineering bacteria for expressing the third recombinant vector of the D-pantolactone hydrolase.
In the preferable technical scheme of the invention, the recombinant engineering bacteria are used for preparing D-pantolactone from DL-pantolactone.
In a preferred technical scheme of the invention, the first recombinant vector comprises an L-pantoate lactone dehydrogenase encoding gene, and preferably, the L-pantoate lactone dehydrogenase encoding gene is derived from any one of rhodococcus erythropolis, mycobacteria, nocardia, streptomyces and actinomycetes.
In the preferred technical scheme of the invention, the L-pantolactone dehydrogenase coding gene is subjected to codon optimization and enzyme cutting sites to obtain an L-pantolactone dehydrogenase gene sequence.
In a preferred embodiment of the present invention, the cleavage site is selected from any one of XhoI and NdeI or a combination thereof.
In the preferable technical scheme of the invention, the L-pantoate lactone dehydrogenase gene sequence is artificially synthesized to prepare the target gene 1, and the nucleotide sequence of the target gene 1 is shown in SEQ ID NO. 1.
In a preferred technical scheme of the invention, the second recombinant vector comprises a ketopantoate lactone reductase coding gene, and preferably, the ketopantoate lactone reductase coding gene is derived from any one of candida magnolifolia, micromonospora and streptomyces.
In the preferred technical scheme of the invention, the ketopantoate lactone reductase coding gene is subjected to codon optimization and enzyme cutting sites to obtain a ketopantoate lactone reductase gene sequence.
In a preferred embodiment of the present invention, the cleavage site is selected from SacI and NotI, or a combination thereof.
In the preferred technical scheme of the invention, the ketopantoate lactone reductase gene sequence is artificially synthesized to prepare a target gene 2, and the nucleotide sequence of the target gene 2 is shown as SEQ ID NO. 2.
In a preferred technical scheme of the invention, the third recombinant vector comprises a D-pantolactone reductase coding gene, and preferably, the D-pantolactone hydrolase coding gene is derived from any one of fusarium moniliforme, fusarium solani and fusarium.
In the preferred technical scheme of the invention, the D-pantoic acid lactone hydrolase coding gene is subjected to codon optimization and enzyme cutting sites to obtain a D-pantoic acid lactone gene sequence.
In a preferred embodiment of the present invention, the cleavage site is selected from any one of XhoI and NdeI or a combination thereof.
In the preferred technical scheme of the invention, the D-pantolactone hydrolase gene sequence is artificially synthesized to prepare the target gene 3, and the nucleotide sequence of the target gene 3 is shown as SEQ ID NO. 3.
In a preferred embodiment of the present invention, the codon optimization is performed according to the codon preference of E.coli.
In a preferred embodiment of the present invention, the vector for recombination is selected from any one of pET-21a plasmid, pET-28a plasmid, pRSFDuet-I plasmid, or a combination thereof.
In a preferred embodiment of the present invention, the method for obtaining the first recombinant vector comprises the following steps: the coding gene or the target gene 1 of the L-pantolactone dehydrogenase or the gene shown as SEQ ID NO: 1 into a first vector to obtain a first recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the second recombinant vector comprises the following steps: the ketopantoate lactone reductase coding gene or the target gene 2 or the gene shown as SEQ ID NO: 2 into a second vector to obtain a second recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the third recombinant vector comprises the following steps: d-pantoic acid lactone hydrolase coding gene or target gene 3 or a gene shown as SEQ ID NO: 3 into a third vector to obtain a third recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fourth recombinant vector comprises the following steps: the coding gene or the target gene 1 of the L-pantolactone dehydrogenase or the gene shown as SEQ ID NO: 1 and ketopantoate lactone reductase coding gene or target gene 2 or a nucleotide sequence shown as SEQ ID NO: 2 into a fourth vector to obtain a fourth recombinant vector, wherein the cloning sequence of the 2 genes or the nucleic acid sequences is not shown in sequence.
In a preferred embodiment of the present invention, the method for obtaining the fifth recombinant vector comprises the following steps: encoding a gene of L-pantolactone dehydrogenase or a target gene 1 or a gene shown as SEQ ID NO: 1, ketopantoate lactone reductase coding gene or target gene 2 or a nucleotide sequence shown as SEQ ID NO: 2, a D-pantolactone hydrolase coding gene or a target gene 3 or a nucleotide sequence shown as SEQ ID NO: 3 into a fifth vector to obtain a fifth recombinant vector, wherein the cloning sequence of the 3 genes or the nucleic acid sequences is not shown in sequence.
In a preferred embodiment of the present invention, any one or a combination of the first recombinant vector, the second recombinant vector, the third recombinant vector, the fourth recombinant vector, or the fifth recombinant vector is introduced into a host cell sequentially or simultaneously to obtain a recombinant engineered bacterium.
In a preferred embodiment of the present invention, the host cell is any one selected from the group consisting of bacillus, yeast, escherichia, pantoea, salmonella, corynebacterium glutamicum, escherichia coli, and pantoea ananatis.
In a preferred technical scheme of the invention, the induction method of the recombinant engineering bacteria comprises the following steps:
s-1, inoculating the recombinant engineering bacteria into an LB culture medium according to the inoculation amount of 1-5%, and culturing for 6-16h at the temperature of 30-40 ℃ and at the speed of 50-500rpm to obtain a first-stage seed solution;
s-2, inoculating the primary seed solution into a TB culture medium according to the inoculation amount of 1-5%, culturing for 6-20h at the temperature of 25-40 ℃ and at the rpm of 50-500, centrifuging, washing with a phosphate buffer solution, and collecting thalli.
In the preferred technical scheme of the invention, the fermentation temperature in the S-1 step is 35-38 ℃, and the rotation speed is 100-300 rpm.
In the preferable technical scheme of the invention, in the S-2 step, the culture is firstly carried out for 0.5-3h under the conditions of 35-38 ℃ and 100-300rpm, and then the culture is carried out for 10-15h under the conditions of 28-30 ℃ and 100-300 rpm.
In the preferable technical scheme of the invention, the LB culture medium comprises ampicillin, kanamycin, yeast powder, tryptone and sodium chloride.
In the preferable technical scheme of the invention, the composition of the LB culture medium comprises 40-60mg/L of ampicillin, 90-110mg/L of kanamycin, 4-6g/L of yeast powder, 8-12 g/L of tryptone and 8-12 g/L of sodium chloride.
In the preferable technical scheme of the invention, the composition of the LB culture medium comprises 50mg/L of ampicillin, 100mg/L of kanamycin, 5g/L of yeast powder, 10g/L of tryptone and 10g/L of sodium chloride.
In the preferable technical scheme of the invention, the TB culture medium comprises ampicillin, kanamycin, tryptone, yeast powder, sodium chloride, glucose and lactose.
In the preferable technical scheme of the invention, the composition of the TB culture medium comprises 40-60mg/L of ampicillin, 90-110mg/L of kanamycin, 18-22g/L of tryptone, 4-6g/L of yeast powder, 4-6g/L of sodium chloride, 1-3g/L of glucose and 0.1-3.0g/L of lactose.
In the preferable technical scheme of the invention, the composition of the TB culture medium comprises 50mg/L of ampicillin, 100mg/L of kanamycin, 20g/L of tryptone, 5g/L of yeast powder, 5g/L of sodium chloride, 2g/L of glucose and 0.1-2.0g/L of lactose.
The invention also aims to provide a construction method of the recombinant engineering bacteria, which comprises the following steps:
(1) introducing any one of the coding gene of L-pantolactone dehydrogenase, the coding gene of ketopantolactone reductase and the coding gene of D-pantolactone hydrolase or the combination thereof into a vector sequentially or synchronously to obtain a recombinant vector;
(2) and (3) introducing the obtained recombinant vector into a host cell to obtain the recombinant engineering bacterium.
In a preferable technical scheme of the invention, the recombinant vector is selected from any one of a third recombinant vector containing a nucleotide sequence of a D-pantoate lactone hydrolase coding gene as shown in SEQ ID No.4, a fourth recombinant vector containing a nucleotide sequence of an L-pantoate lactone dehydrogenase coding gene as shown in SEQ ID No.1 and a nucleotide sequence of a ketopantoate lactone reductase coding gene as shown in SEQ ID No. 2.
In a preferred embodiment of the present invention, the method for obtaining the third recombinant vector comprises the following steps: d-pantoic acid lactone hydrolase coding gene or target gene 3 or a gene shown as SEQ ID NO: 3 into a third vector to obtain a third recombinant vector.
In a preferred embodiment of the present invention, the method for obtaining the fourth recombinant vector comprises the following steps: encoding a gene of L-pantolactone dehydrogenase or a target gene 1 or a gene shown as SEQ ID NO: 1 and ketopantoate lactone reductase coding gene or target gene 2 or a nucleotide sequence shown as SEQ ID NO: 2 into a fourth vector to obtain a fourth recombinant vector, wherein the cloning sequence of the two genes or nucleic acid sequences is not sequential.
In a preferred embodiment of the present invention, the vector for recombination is selected from any one of pET-21a plasmid, pET-28a plasmid and pRSFDuet-I plasmid, or a combination thereof.
In a preferred embodiment of the present invention, any one or a combination of the third recombinant vector and the fourth recombinant vector is introduced into a host cell sequentially or simultaneously to obtain a recombinant engineered bacterium.
In a preferred technical scheme of the invention, the recombinant engineering bacteria comprise a fourth recombinant vector capable of co-expressing L-pantoate lactone dehydrogenase and ketopantoate lactone reductase.
In a preferred technical scheme of the invention, the recombinant engineering bacteria also comprise a third recombinant vector for expressing D-pantolactone hydrolase, or are combined with a second recombinant engineering bacteria for expressing the third recombinant vector of the D-pantolactone hydrolase.
In a preferred embodiment of the present invention, the host cell is any one selected from the group consisting of bacillus, yeast, escherichia, pantoea, salmonella, corynebacterium glutamicum, escherichia coli, and pantoea ananatis.
The invention also aims to provide an induced expression method of the recombinant engineering bacteria, which comprises the following steps:
s-1, inoculating the recombinant engineering bacteria into an LB culture medium according to the inoculation amount of 1-5%, and culturing for 6-16h at the temperature of 30-40 ℃ and at the speed of 50-500rpm to obtain a first-stage seed solution;
s-2, inoculating the primary seed solution into a TB culture medium according to the inoculation amount of 1-5%, culturing for 6-20h at the temperature of 25-40 ℃ and at the speed of 50-500rpm, centrifuging, washing with a phosphate buffer solution, and collecting thalli.
In the preferred technical scheme of the invention, in the step S-1, the fermentation temperature is 35-38 ℃, and the rotation speed is 100-300 rpm.
In the preferable technical scheme of the invention, the S-2 step is firstly cultured for 0.5-3h under the conditions of 35-38 ℃ and 100-300rpm and then cultured for 10-15h under the conditions of 28-30 ℃ and 100-300 rpm.
In the preferable technical scheme of the invention, the LB culture medium comprises ampicillin, kanamycin, yeast powder, tryptone and sodium chloride.
In the preferable technical scheme of the invention, the composition of the LB culture medium comprises 40-60mg/L of ampicillin, 90-110mg/L of kanamycin, 4-6g/L of yeast powder, 8-12 g/L of tryptone and 8-12 g/L of sodium chloride.
In the preferable technical scheme of the invention, the composition of the LB culture medium comprises 50mg/L of ampicillin, 100mg/L of kanamycin, 5g/L of yeast powder, 10g/L of tryptone and 10g/L of sodium chloride.
In the preferable technical scheme of the invention, the TB culture medium comprises ampicillin, kanamycin, tryptone, yeast powder, sodium chloride, glucose and lactose.
In the preferable technical scheme of the invention, the composition of the TB culture medium comprises 40-60mg/L of ampicillin, 90-110mg/L of kanamycin, 18-22g/L of tryptone, 4-6g/L of yeast powder, 4-6g/L of sodium chloride, 1-3g/L of glucose and 0.1-3.0g/L of lactose.
In the preferable technical scheme of the invention, the composition of the TB culture medium comprises 50mg/L of ampicillin, 100mg/L of kanamycin, 20g/L of tryptone, 5g/L of yeast powder, 5g/L of sodium chloride, 2g/L of glucose and 0.1-2.0g/L of lactose.
Another object of the present invention is to provide a method for preparing D-pantolactone, comprising the steps of: placing DL-pantoic acid lactone with the concentration of 10-300g/L into a reaction system with the recombinant engineering bacteria OD value of 1-5, and placing the reaction system under the conditions of 30-40 ℃ and pH5-7 for 20-40h to prepare the D-pantoic acid lactone.
In a preferred embodiment of the present invention, NADPH is optionally added, and preferably, the concentration of NADPH in the reaction system is 10 to 100mmol/L, preferably 30 to 90mmol/L, and more preferably 50 to 70 mmol/L.
In the preferable technical scheme of the invention, the OD value of the recombinant engineering bacteria is 2-3.
In a preferred technical scheme of the invention, the recombinant engineering bacteria can express any one or combination of L-pantolactone dehydrogenase, ketopantolactone reductase and D-pantolactone hydrolase.
In a preferred embodiment of the present invention, the concentration of DL-pantoic acid lactone is 50-250g/L, preferably 100-200 g/L.
In the preferred technical scheme of the invention, the temperature of the reaction system is 35-37 ℃.
In the preferred technical scheme of the invention, the reaction time is 25-35 h.
In the preferred technical scheme of the invention, the pH of the reaction system is 5.5-6.5, and the preferred pH is 5.8-6.2.
In a preferred embodiment of the present invention, the pH adjuster is any one selected from the group consisting of ammonia water, sodium hydroxide, sodium bicarbonate, triethylamine, potassium hydroxide, sodium phosphate, sodium citrate, sodium malate, phosphate buffer, Tris buffer, and sulfuric acid.
In the preferred technical scheme of the invention, the reaction solution is filtered, the filtrate is collected, the pH value is adjusted to 1-3, and the filtrate is placed.
In the preferred technical scheme of the invention, the ee value of the obtained D-pantolactone is more than or equal to 95 percent, preferably more than or equal to 96 percent, more preferably more than or equal to 97 percent, still more preferably more than or equal to 98 percent, and still more preferably more than or equal to 99 percent.
The invention also aims to provide application of the recombinant engineering bacteria in preparing D-pantolactone from DL-pantolactone.
In a preferred embodiment of the present invention, the D-pantolactone is used for preparing a panto-compound, preferably the panto-compound is selected from any one of D-pantolactone, D-pantothenic acid, D-calcium pantothenate, D-panthenol and pantethine.
Unless otherwise indicated, when the present invention relates to percentages between liquids, said percentages are volume/volume percentages; when the invention relates to percentages between liquid and solid, said percentages are volume/weight percentages; the invention relates to the percentages between solid and liquid, said percentages being weight/volume percentages; the balance being weight/weight percent.
1. Conversion rate
Instruments and working conditions: shimadzu LC-16 liquid chromatograph and chromatographic columnIE5 μm, 4.6 × 250mm, column temperature 30 deg.C, collection time 30min, wavelength 210nm, flow rate 1.0ml/min, mobile phase 0.05mol/L sodium dihydrogen phosphate water solution: methanol 60: 40.
The experimental steps are as follows: respectively diluting the reaction solution by 100 times when the conversion time T is 0 and T is M (M is any value more than 0), filtering, injecting sample with the sample amount of 10ul, and respectively recording the peak area S of L-pantolactone 0 And S M 。
Conversion rate (M time) =(S 0 -S M )/S 0 。
2. ee value calculation formula
ee value ═ L-pantolactone content (D-pantolactone content)/(D-pantolactone content + L-pantolactone content)
Compared with the prior art, the invention has the following beneficial technical effects:
1. the invention provides a recombinant engineering bacterium and a construction method thereof, the recombinant engineering bacterium can co-express an L-pantolactone dehydrogenase encoding gene, a ketopantolactone reductase encoding gene and a D-pantolactone hydrolase encoding gene through induction culture, is used for efficiently preparing D-pantolactone with high optical purity, and has the advantages of simple operation, environmental protection, suitability for industrial production and the like.
2. The invention also provides a method for synthesizing D-pantolactone by efficiently catalyzing DL-pantolactone or L-pantolactone by using the enzyme induced by the recombinant engineering bacteria, which obviously improves the selectivity and reaction efficiency of L-pantolactone dehydrogenase and the product conversion rate.
3. The method does not adopt a chemical resolution reagent, avoids the cyclic racemization of the L-pantoic acid lactone, shortens the production period, and has the advantages of simple and convenient operation, environmental protection, better cost, suitability for large-scale industrial production and the like.
Detailed Description
The present invention is further illustrated in detail by the following examples. These examples and experimental examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Example 1 construction of a Dual-enzyme Co-expression recombinant engineered bacterium
1. Design and Synthesis of Gene of interest
Step one, carrying out codon optimization on a nucleotide sequence of an L-pantoate lactone dehydrogenase encoding gene derived from Humibacter sp.BT305 (actinomycetes) according to codon preference of escherichia coli (E.coli), and adding XhoI and NdeI enzyme cutting sites to obtain an L-pantoate lactone dehydrogenase modified gene sequence, wherein the nucleotide sequence is shown as SEQ ID NO. 1;
and step two, carrying out codon optimization on the nucleotide sequence of the ketopantoate lactone reductase coding gene derived from the candida magnolifolia according to the codon preference of escherichia coli (E.coli), and adding SacI and NotI enzyme cutting sites to obtain a D-ketopantoate lactone modified gene sequence, wherein the nucleotide sequence is shown as SEQ ID No. 2.
And step three, carrying out codon optimization on the nucleotide sequence of the D-pantolactone hydrolase coding gene derived from Fusarium moniliforme CGMCC 0536 (Fusarium moniliforme) according to the codon preference of escherichia coli (E.coli), and adding XhoI and NdeI enzyme cutting sites to obtain a D-pantolactone hydrolase modified gene sequence, wherein the nucleotide sequence is shown as SEQ ID NO. 3.
And step four, synthesizing nucleotide sequences shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3 to prepare a target gene 1, a target gene 2 and a target gene 3.
2. Construction of recombinant engineering bacteria
Step one, taking a DNA molecule of the target genome 1 as a template, carrying out PCR amplification on lpldh-for and lpldh-rev by using primers, carrying out electrophoresis on 1% agarose gel to separate PCR products, and recovering a gene fragment of the target genome 1 by using a gel recovery kit.
The primer sequences are as follows: (restriction sites underlined)
lpldh-for:GGAATTCCATATGATGAACCCGTGGTTTGAAAC
lpldh-rev:CCGCTCGAGTGCGCTTTCTGCTTCTGC
The PCR system was as follows:
the PCR process was as follows: pre-denaturation at 95 deg.C for 5min, denaturation at 95 deg.C for 30s, annealing at 57 deg.C for 30s, extension at 72 deg.C for 1min for 30s, circulating for 28 times, keeping at 72 deg.C for 10min, cooling to 4 deg.C, and storing in refrigerator at 4 deg.C for use.
And step two, taking the DNA molecule of the target genome 2 as a template, carrying out PCR amplification on KPR-for and KPR-rev by adopting a primer pair, carrying out electrophoresis separation on a PCR product by using 1% agarose gel, and recovering the gene fragment of the target genome 2 by using a gel recovery kit.
The primer sequences are as follows: (restriction sites underlined)
KPR-for:
GGAATTCCATATGATGGCTAAAAACTTCTCTAACGTTGAATACC
KPR-rev:CCGCTCGAGCGGCAGGGTGTAACCACCGTCAAC
The PCR system was as follows:
the PCR process was as follows:
pre-denaturation at 95 deg.C for 5min, denaturation at 95 deg.C for 30s, annealing at 55 deg.C for 30s, extension at 72 deg.C for 1min, circulation for 28 times, keeping at 72 deg.C for 10min, cooling to 4 deg.C, and storing in refrigerator at 4 deg.C for use.
And step three, double-digesting the pRSFDuet-I plasmid and the gene fragment of the genome 1 by using restriction enzymes XhoI and NdeI, recovering a vector framework and a digested PCR product, connecting the vector framework and the digested PCR product by using T4 DNA ligase, transforming the connected product (named as pRSF-lpldh) into E.coli BL21(DE3) competent cells, screening positive clones, extracting plasmids, performing sequencing identification, and naming the correct clone as E-pRSF-lpldh.
And step four, carrying out double enzyme digestion on pRSF-lpldh plasmid and the gene fragment of the genome 2 by using restriction enzymes SacI and NotI, recovering a vector skeleton and an enzyme digestion PCR product, connecting the vector skeleton and the enzyme digestion PCR product by using T4 DNA ligase, transforming the connection product (named as pRSFDuet-lpldh-kpr) into E.coli BL21(DE3) competent cells, screening positive clones, extracting plasmids for sequencing identification, and naming the correct clone as E-lpldh-kpr to prepare the double-plasmid two-enzyme recombinant engineering bacteria for co-expressing L-pantoate dehydrogenase and ketopantoate lactone reductase.
Example 2 construction of two-plasmid three-enzyme Co-expression recombinant engineering bacteria
1. Design and Synthesis of Gene of interest
Step one, carrying out codon optimization on a nucleotide sequence of an L-pantoate lactone dehydrogenase encoding gene derived from Humibacter sp.BT305 according to codon preference of escherichia coli (E.coli), and adding XhoI and NdeI enzyme cutting sites to obtain an L-pantoate lactone dehydrogenase modified gene sequence, wherein the nucleotide sequence is shown as SEQ ID No. 1;
and step two, carrying out codon optimization on the nucleotide sequence of the ketopantoate lactone reductase coding gene derived from the candida magnolifolia according to the codon preference of escherichia coli (E.coli), and adding SacI and NotI enzyme cutting sites to obtain a D-ketopantoate lactone modified gene sequence, wherein the nucleotide sequence is shown as SEQ ID No. 2.
And step three, carrying out codon optimization on the nucleotide sequence derived from the D-pantolactone hydrolase encoding gene of the fusarium moniliforme according to the codon preference of escherichia coli (E.coli), and adding XhoI and NdeI enzyme cutting sites to obtain a D-pantolactone hydrolase modification gene sequence, wherein the nucleotide sequence is shown as SEQ ID NO. 3.
And step four, synthesizing nucleotide sequences shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3 to obtain the target gene 1, the target gene 2 and the target gene 3.
2. Construction of recombinant engineering bacteria
Step one, taking a DNA molecule of a target genome 1 as a template, performing PCR amplification on lpldh-for and lpldh-rev by using primers, performing electrophoresis on 1% agarose gel to separate a PCR product, and recovering a gene fragment of the target genome 1 by using a gel recovery kit.
The primer sequences are as follows: (restriction sites underlined)
lpldh-for:GGAATTCCATATGATGAACCCGTGGTTTGAAAC
lpldh-rev:CCGCTCGAGTGCGCTTTCTGCTTCTGC
The PCR system was as follows:
the PCR process was as follows: pre-denaturing at 95 ℃ for 5min, denaturing at 95 ℃ for 30s, annealing at 57 ℃ for 30s, extending at 72 ℃ for 1min for 30s, circulating for 28 times, keeping the temperature at 72 ℃ for 10min, cooling to 4 ℃, and storing in a refrigerator at 4 ℃ for later use.
And step two, taking the DNA molecule of the target genome 2 as a template, carrying out PCR amplification on KPR-for and KPR-rev by adopting a primer pair, carrying out electrophoresis separation on a PCR product by using 1% agarose gel, and recovering the gene fragment of the target genome 2 by using a gel recovery kit.
The primer sequences are as follows: (restriction sites underlined)
KPR-for:
GGAATTCCATATGATGGCTAAAAACTTCTCTAACGTTGAATACC
KPR-rev:CCGCTCGAGCGGCAGGGTGTAACCACCGTCAAC
The PCR system was as follows:
the PCR process was as follows:
pre-denaturation at 95 deg.C for 5min, denaturation at 95 deg.C for 30s, annealing at 55 deg.C for 30s, extension at 72 deg.C for 1min, circulation for 28 times, keeping at 72 deg.C for 10min, cooling to 4 deg.C, and storing in refrigerator at 4 deg.C for use.
And step three, double-digesting the pRSFDuet-I plasmid and the gene fragment of the genome 1 by using restriction enzymes XhoI and NdeI, recovering a vector framework and a digested PCR product, connecting the vector framework and the digested PCR product by using T4 DNA ligase, transforming the connected product (named as pRSF-lpldh) into E.coli BL21(DE3) competent cells, screening positive clones, extracting plasmids, sequencing and identifying, and naming the correct clone as E-pRSF-lpldh.
And step four, carrying out double enzyme digestion on pRSF-lpldh plasmid and the gene fragment of the genome 2 by using restriction enzymes SacI and NotI, recovering a vector skeleton and an enzyme digestion PCR product, connecting the vector skeleton and the enzyme digestion PCR product by using T4 DNA ligase, transforming the connection product (named as pRSFDuet-lpldh-kpr) into E.coli BL21(DE3) competent cells, screening positive clones, extracting plasmids for sequencing identification, and naming the correct clone as E-lpldh-kpr to prepare the double-plasmid two-enzyme recombinant engineering bacteria for co-expressing L-pantoate dehydrogenase and ketopantoate lactone reductase.
And step five, taking a DNA molecule of the target genome 3 as a template, performing PCR amplification on HYD-for and HYD-rev by using a primer pair, carrying out electrophoresis separation on a PCR product by using 1% agarose gel, and recovering a gene fragment of the target genome 3 by using a gel recovery kit.
The primer sequences are as follows: (restriction sites underlined)
HYD-for:GGAATTCCATATGATGGCTAAGCTTCCTTCTAC
HYD-rev:CCGCTCGAGCTAATCATAGAGCTTGGGACCC
The PCR system was as follows:
the PCR process was as follows:
pre-denaturation at 95 deg.C for 5min, denaturation at 95 deg.C for 30s, annealing at 53 deg.C for 30s, extension at 72 deg.C for 1min, circulation for 28 times, keeping at 72 deg.C for 10min, cooling to 4 deg.C, and storing in refrigerator at 4 deg.C for use.
And sixthly, double-digesting the PCR product of the pET-21a plasmid and the genome 3 by using restriction enzyme XhoI and NdeI, recovering a vector framework and the PCR product, connecting the vector framework and the PCR product by using T4 DNA ligase, transforming the connection product (named as pET-hyd) into E-lpldhh-kpr competent cells, screening positive clones, extracting the plasmid, performing sequencing identification, and naming the correct clone as E-lpldhh-kpr-hyd.
Example 3 inducible expression of recombinant engineered bacterium E-lpldh-kpr
The recombinant engineering bacterium E-lpldh-kpr prepared in the example 1 is inoculated in 5mL LB culture medium and is cultured overnight at the temperature of 37 ℃ and the speed of 200 rpm;
inoculating the seeds into 100mL of TB culture medium according to the inoculation amount of 2%, culturing for 2h under the conditions of 37 ℃ and 200rpm, adjusting the culture temperature to 30 ℃, and continuing to culture for 15 h;
6600rpm for 3min, discarding supernatant, washing with 0.2moL/L phosphoric acid buffer (pH6.5) for 2 times, and collecting thallus.
Wherein, the LB culture medium comprises the following components: 100mg/L kanamycin, 5g/L yeast powder, 10g/L tryptone and 10g/L sodium chloride.
The composition of TB medium is as follows: tryptone 20g/L, yeast powder 5g/L, sodium chloride 5g/L, glucose 2g/L, lactose 0.1-2.0g/L, ampicillin 50mg/L, and kanamycin 100 mg/L.
Example 4 inducible expression of recombinant engineered bacterium E-lpldh-kpr-hyd
The recombinant expression cell E-lpldh-kpr-hyd prepared in the example 2 is inoculated in 5mL LB culture medium and is cultured overnight at the temperature of 37 ℃ and the speed of 200rpm to obtain a seed solution;
inoculating the seed solution into 100mL TB culture medium according to the inoculation amount of 2%, culturing for 2h under the conditions of 37 ℃ and 200rpm, adjusting the culture temperature to 30 ℃, and continuing to culture for 15 h;
6600rpm for 3min, discarding supernatant, washing with 0.2moL/L phosphoric acid buffer (pH6.5) for 2 times, and collecting thallus.
Wherein, the composition of the LB culture medium is as follows: 50mg/L of ampicillin, 100mg/L of kanamycin, 5g/L of yeast powder, 10g/L of tryptone and 10g/L of sodium chloride.
The composition of TB medium is as follows: tryptone 20g/L, yeast powder 5g/L, sodium chloride 5g/L, glucose 2g/L, lactose 0.1-2.0g/L, ampicillin 50mg/L, kanamycin 100 mg/L.
Example 5 conversion of DL-pantoic acid lactone
Adding 130g of DL-pantoic acid lactone into a reaction vessel, adding water until the total volume is 1L, and stirring to dissolve; the pH of the solution was adjusted to 6.2 with 20-25% ammonia, the temperature was raised to 37 ℃ and the recombinant engineered bacterial cells (OD 2) collected in example 1 were added, and the mixture was stirred at 37 ℃ for 30 hours to obtain a reaction solution. The high performance liquid chromatography detection of the reaction liquid shows that the final concentration of D-pantolactone is 113.49g/L, the conversion rate of DL-pantolactone is 87.3 percent, and the ee value is 74.6 percent.
Example 6 conversion of DL-pantolactone
Adding 130g of DL-pantolactone into a reaction vessel, adding water until the total volume is 1L, and stirring to dissolve; the pH of the solution was adjusted to 6.2 with 20-25% aqueous ammonia, the temperature was raised to 37 ℃ and the recombinant engineered bacterial cells (OD 2) collected in example 1 and 50mM NADPH (reaction system concentration) were added, and the mixture was left at 37 ℃ and stirred for 30 hours to obtain a reaction solution. The reaction solution is subjected to high performance liquid chromatography detection, the final concentration of D-pantolactone is 124.93g/L, the conversion rate of DL-pantolactone is 96.1%, and the ee value is 92.2%.
Example 7 conversion of DL-pantoic acid lactone
Adding 130g of DL-pantolactone into a reaction vessel, adding water until the total volume is 1L, and stirring to dissolve; the pH of the solution was adjusted to 6.2 with 20-25% ammonia, the temperature was raised to 37 ℃ and the recombinant engineered bacteria (OD 2) collected in example 2 was added thereto, and the mixture was stirred at 37 ℃ for 30 hours to obtain a reaction solution. The reaction solution is subjected to high performance liquid chromatography detection, the final concentration of D-pantoic acid is 146.67g/L, and the conversion rate of DL-pantoic lactone is 99.1%.
And (3) passing the reaction solution through a ceramic membrane, collecting the clear solution of the ceramic membrane and passing through a nanofiltration membrane, collecting the clear solution of the nanofiltration membrane, adjusting the pH to 1.5 with concentrated sulfuric acid, and standing for 30min to obtain a D-pantolactone solution, wherein the concentration of the D-pantolactone is 128.83g/L, and the ee value is 98.2%.
Example 8 conversion of DL-pantolactone
Adding 130g of DL-pantoic acid lactone into a reaction vessel, adding water until the total volume is 1L, and stirring to dissolve; the pH of the solution was adjusted to 6.2 with 20-25% aqueous ammonia, the temperature was raised to 37 ℃ and the recombinant engineered bacteria (OD 2) collected in example 2 and 50mM NADPH were added to the solution, and the mixture was stirred at 37 ℃ for 30 hours to obtain a reaction solution. The reaction solution is subjected to high performance liquid chromatography detection, the final concentration of D-pantoic acid is 147.97g/L, and the conversion rate of DL-pantoic acid lactone is 99.98%.
And (3) passing the reaction solution through a ceramic membrane, collecting a ceramic membrane clear solution and a nanofiltration membrane, collecting a nanofiltration membrane clear solution, adjusting the pH to be about 1.5, and standing for 30min to obtain a D-pantolactone solution, wherein the concentration of D-pantolactone is 129.97g/L, and the ee value is 99.95%.
The above description of the specific embodiments of the present invention is not intended to limit the present invention, and those skilled in the art may make various changes and modifications according to the present invention without departing from the spirit of the present invention, which is defined in the appended claims.
Sequence listing
<110> Anhui Hua constant Biotech, Inc
Bayannur Huaheng Biotechnology Co.,Ltd.
QINHUANGDAO HUAHENG BIOENGINEERING Co.,Ltd.
HEFEI HUAHENG BIOLOGICAL ENGINEERING Co.,Ltd.
<120> recombinant engineering bacterium, construction method and application thereof
<150> 2020110463081
<151> 2020-09-29
<150> 2021109408571
<151> 2021-08-17
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1176
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
atggctaaaa acgctttctt cgaaaccgtt gctgaagctc agcgtcgtgc taaaaaacgt 60
ctgccgaaat ctgtttacgc tgctctggtt gctggttctg aaaaaggtct gaccgttgac 120
gacaacgttg ctgctttctc tgaactgggt ttcgctccgc acgctgctgg tctgtctgac 180
aaacgtgaaa tgtctaccac catcatgggt caggacatct ctctgccggt tatgatctct 240
ccgaccggtg ttcaggctgt tcacccggac ggtgaagttg ctgttgctcg tgctgctgct 300
gctcgtggta ccgctatcgg tctgtcttct ttcgcttcta aatctatcga agaagttgct 360
gctgctaacc cgcaggtttt cttccagatg tactgggttg gttctcgtga cgttctgctg 420
cagcgtatgg aacgtgctcg tgctgctggt gctaaaggtc tgatcatcac caccgactgg 480
tctttctctt acggtcgtga ctggggttct ccgtctatcc cggaaaaaat ggacctgaaa 540
gctatgttcc agttcgctcc ggaaggtatc atgcgtccga aatggctgct ggaattcgct 600
aaaaccggta aaatcccgga cctgaccacc ccgaacctgg ctgctccggg tcagccggct 660
ccgaccttct tcggtgctta cggtgaatgg atgcagaccc cgctgccgac ctgggaagac 720
atcgcttggc tgcgtgaaca gtggggtggt ccgttcatgc tgaaaggtat catgcgtatc 780
gacgacgcta aacgtgctgt tgacgctggt gtttctgcta tctctgtttc taaccacggt 840
ggtaacaacc tggacggtac cccggctccg atccgtgttc tgccgggtat cgctgaagct 900
gttggtgacc aggttgaagt tgttctggac ggtggtatcc gtcgtggtgg tgacgttgtt 960
aaagctctgg ctctgggtgc taaagctgtt atgctgggtc gtgcttacct gtggggtctg 1020
tctgctaacg gtcaggctgg tgttgaaaac gttctggacc tgatgcgtat gggtatcgac 1080
tctggtctga tgggtctggg tcactcttct atcaccgaac tgtctccggc tgacctggtt 1140
atcccggaag gtttcacccg taccctgggt gcttct 1176
<210> 2
<211> 849
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
atggctaaaa acttctctaa cgttgaatac ccggctccgc cgccggctca caccaaaaac 60
gaatctctgc aggttctgga cctgttcaaa ctgaacggta aagttgcttc tatcaccggt 120
tcttcttctg gtatcggtta cgctctggct gaagctttcg ctcaggttgg tgctgacgtt 180
gctatctggt acaactctca cgacgctacc ggtaaagctg aagctctggc taaaaaatac 240
ggtgttaaag ttaaagctta caaagctaac gtttcttctt ctgacgctgt taaacagacc 300
atcgaacagc agatcaaaga cttcggtcac ctggacatcg ttgttgctaa cgctggtatc 360
ccgtggacca aaggtgctta catcgaccag gacgacgaca aacacttcga ccaggttgtt 420
gacgttgacc tgaaaggtgt tggttacgtt gctaaacacg ctggtcgtca cttccgtgaa 480
cgtttcgaaa aagaaggtaa aaaaggtgct ctggttttca ccgcttctat gtctggtcac 540
atcgttaacg ttccgcagtt ccaggctacc tacaacgctg ctaaagctgg tgttcgtcac 600
ttcgctaaat ctctggctgt tgaattcgct ccgttcgctc gtgttaactc tgtttctccg 660
ggttacatca acaccgaaat ctctgacttc gttccgcagg aaacccagaa caaatggtgg 720
tctctggttc cgctgggtcg tggtggtgaa accgctgaac tggttggtgc ttacctgttc 780
ctggcttctg acgctggttc ttacgctacc ggtaccgaca tcatcgttga cggtggttac 840
accctgccg 849
<210> 3
<211> 1146
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
atggcaaaac taccctcaac agctcaaata attgatcaga aatccttcaa cgtgctgaag 60
gacgtgccac cgccagcggt ggctaatgat tccttggttt ttacctggcc tggtgttacg 120
gaggaaagct tggttgaaaa accgtttcac gtgtacgatg aagagttcta cgacgtgatc 180
ggcaaggacc cgtccttgac cctgatcgct accagtgata cggacccgat tttccatgaa 240
gccgtcgtgt ggtatccgcc gaccgaggag gtgttctttg ttcagaacgc aggcgctccg 300
gctgcgggca ctggtctgaa caaaagcagc attatccaga aaatttcgct gaaagaagcg 360
gatgaggttc gtaagggcaa gaaagatgag gttaaagttg cagttgttga ttctaatccg 420
caggtcatca acccgaacgg cggtacctat tacaaaggca acattatctt cgcgggcgaa 480
ggtcaaggtg acgatgtgcc gagcgcactg tacctgatga atccgctccc gccgtacaac 540
accactacgc tgctgaataa ctattttggt cgccagttca acagcttgaa cgatgttggt 600
atcaacccgc gtaatggcga cctgtatttc accgacaccc tttatggcta tctgcaggat 660
tttcgtccgg ttccaggtct gcgtaaccaa gtctaccgct acaacttcga tacgggtgcg 720
gtgacggtgg tcgccgacga cttcaccttg ccgaacggta ttggcttcgg tccggatggt 780
aaaaaggtgt atgttactga cacaggcatc gccctgggtt tttacggccg caacctgagc 840
tccccggcgt ctgtgtacag ctttgacgta aatcaagatg gcaccttaca aaacagaaag 900
acctttgcgt atgtcgcgag ctttatcccg gacggggttc acaccgacag caaaggtcgt 960
gtttacgcag gatgcggtga cggcgttcat gtgtggaatc cgtctggcaa gctgatcggt 1020
aagatctata ccggcaccgt tgcggcaaat ttccagttcg ctggtaaggg ccgtatgatt 1080
attaccggtc aaaccaagct attttacgtg accttgggtg cgtctggtcc gaaactgtac 1140
gactaa 1146
Claims (10)
1. A recombinant vector contains any one or more recombinant vectors of which the nucleotide sequence of an L-pantolactone dehydrogenase encoding gene is shown as SEQ ID No.1, the nucleotide sequence of a ketopantolactone reductase encoding gene is shown as SEQ ID No.2 and the nucleotide sequence of a D-pantolactone hydrolase encoding gene is shown as SEQ ID No. 3.
2. The recombinant vector according to claim 1, wherein the recombinant vector optionally comprises any one of a fourth recombinant vector comprising the nucleotide sequence of the L-pantolactone dehydrogenase-encoding gene shown in SEQ ID No.1 and the nucleotide sequence of the ketopantolactone reductase-encoding gene shown in SEQ ID No.2 or a fifth recombinant vector comprising the nucleotide sequence of the L-pantolactone dehydrogenase-encoding gene shown in SEQ ID No.1, the nucleotide sequence of the ketopantolactone reductase-encoding gene shown in SEQ ID No.2 and the nucleotide sequence of the D-pantolactone hydrolase-encoding gene shown in SEQ ID No. 3.
3. A recombinant engineered bacterium comprising any one or a combination of a first recombinant vector capable of expressing L-pantolactone dehydrogenase, a second recombinant vector expressing ketopantolactone reductase and a third recombinant vector expressing D-pantolactone hydrolase;
and/or the recombinant engineering bacteria comprise a fourth recombinant vector capable of co-expressing L-pantoate dehydrogenase and ketopantoate reductase;
and/or the recombinant engineering bacteria comprise a fifth recombinant vector capable of co-expressing L-pantolactone dehydrogenase, ketopantolactone reductase and D-pantolactone hydrolase.
4. The recombinant engineered bacterium of claim 3, wherein the recombinant engineered bacterium comprises a fourth recombinant vector capable of co-expressing L-pantolactone dehydrogenase and ketopantolactone reductase; preferably, the recombinant engineering bacteria also comprise a third recombinant vector for expressing D-pantolactone hydrolase, or are combined with a second recombinant engineering bacteria for expressing the third recombinant vector for expressing the D-pantolactone hydrolase.
5. A construction method of recombinant engineering bacteria comprises the following steps:
(1) respectively introducing any one or combination of an L-pantolactone dehydrogenase encoding gene, a ketopantolactone reductase encoding gene and a D-pantolactone hydrolase encoding gene into a vector to obtain a recombinant vector;
(2) and (3) introducing the obtained recombinant vector into a host cell to obtain the recombinant engineering bacterium.
6. An inducible expression method of recombinant engineering bacteria comprises the following steps:
s-1, inoculating the recombinant engineering bacteria into an LB culture medium according to the inoculation amount of 1-5%, and culturing for 6-16h at the temperature of 30-40 ℃ and at the speed of 50-500rpm to obtain a first-stage seed solution;
s-2, inoculating the primary seed solution into a TB culture medium according to the inoculation amount of 1-5%, culturing for 6-20h at the temperature of 25-40 ℃ and at the speed of 50-500rpm, centrifuging, washing with a phosphate buffer solution, and collecting thalli.
7. A preparation method of D-pantoic acid lactone comprises the following steps: placing DL-pantoic acid lactone with concentration of 10-300g/L into a reaction system with recombinant engineering bacteria OD value of 1-5, and preparing D-pantoic acid lactone at 30-40 deg.C and pH of 5-7.
8. The production process according to claim 7, wherein NADPH is optionally added, preferably, the concentration of NADPH in the reaction system is 10 to 100mmol/L, preferably 30 to 90mmol/L, more preferably 50 to 70 mmol/L.
9. The process according to any one of claims 7 to 8, wherein the recombinant engineered bacterium can express any one or a combination of L-pantolactone dehydrogenase, ketopantolactone reductase and D-pantolactone hydrolase.
10. The use of the recombinant engineered bacteria of any one of claims 3-4 for the preparation of D-pantolactone from DL-pantolactone.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020110463081 | 2020-09-29 | ||
CN202011046308.1A CN113106129A (en) | 2020-09-29 | 2020-09-29 | Preparation method of D pantolactone with high conversion rate |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115011623A true CN115011623A (en) | 2022-09-06 |
Family
ID=76709094
Family Applications (13)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011046308.1A Withdrawn CN113106129A (en) | 2020-09-29 | 2020-09-29 | Preparation method of D pantolactone with high conversion rate |
CN202110942171.6A Pending CN115044594A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and application thereof in efficient conversion of L-pantolactone |
CN202110940857.1A Pending CN114426977A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and construction method and application thereof |
CN202110941962.7A Pending CN114426978A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and construction method and application thereof |
CN202110942787.3A Pending CN114426979A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and construction method and application thereof |
CN202111084984.2A Pending CN115011623A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and construction method and application thereof |
CN202111087987.1A Pending CN115029364A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and construction method and application thereof |
CN202111087303.8A Pending CN114774446A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and construction method and application thereof |
CN202111085127.4A Pending CN115011624A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and application thereof in efficient conversion of L-pantolactone |
CN202111135111.XA Withdrawn CN114457130A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and construction method and application thereof |
CN202111133610.5A Withdrawn CN114457128A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and construction method and application thereof |
CN202111135083.1A Withdrawn CN114457129A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and application thereof in efficient conversion of L-pantolactone |
CN202111132818.5A Withdrawn CN114457127A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and construction method and application thereof |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011046308.1A Withdrawn CN113106129A (en) | 2020-09-29 | 2020-09-29 | Preparation method of D pantolactone with high conversion rate |
CN202110942171.6A Pending CN115044594A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and application thereof in efficient conversion of L-pantolactone |
CN202110940857.1A Pending CN114426977A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and construction method and application thereof |
CN202110941962.7A Pending CN114426978A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and construction method and application thereof |
CN202110942787.3A Pending CN114426979A (en) | 2020-09-29 | 2021-08-17 | Recombinant engineering bacterium and construction method and application thereof |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111087987.1A Pending CN115029364A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and construction method and application thereof |
CN202111087303.8A Pending CN114774446A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and construction method and application thereof |
CN202111085127.4A Pending CN115011624A (en) | 2020-09-29 | 2021-09-16 | Recombinant engineering bacterium and application thereof in efficient conversion of L-pantolactone |
CN202111135111.XA Withdrawn CN114457130A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and construction method and application thereof |
CN202111133610.5A Withdrawn CN114457128A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and construction method and application thereof |
CN202111135083.1A Withdrawn CN114457129A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and application thereof in efficient conversion of L-pantolactone |
CN202111132818.5A Withdrawn CN114457127A (en) | 2020-09-29 | 2021-09-27 | Recombinant engineering bacterium and construction method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (13) | CN113106129A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113604371B (en) * | 2021-08-03 | 2023-06-16 | 合肥学院 | Yeast strain HF-21 and method for preparing D-pantolactone by double-phase catalysis thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1293194C (en) * | 2004-08-03 | 2007-01-03 | 江南大学 | D-Pantothe internal ester hydrolase c DNA and its clone expression and application |
ES2541538T3 (en) * | 2004-12-22 | 2015-07-21 | The Michigan Biotechnology Institute | Recombinant microorganisms for increased production of organic acids |
CN1935977B (en) * | 2006-10-19 | 2010-06-09 | 华东理工大学 | Levo lactone hydrolase producing fungus, and its method for preparing chiral hydroxy acid |
CN104388373A (en) * | 2014-12-10 | 2015-03-04 | 江南大学 | Construction of escherichia coli system with coexpression of carbonyl reductase Sys1 and glucose dehydrogenase Sygdh |
CN105132487B (en) * | 2015-07-24 | 2019-04-09 | 雅本化学股份有限公司 | A kind of regenerating coenzyme system and preparation method thereof |
CN106676051B (en) * | 2016-10-31 | 2019-07-05 | 中国科学院微生物研究所 | It is a kind of to prepare the method and its application for efficiently synthesizing pantothenic acid genetic engineering bacterium |
CN109456908A (en) * | 2018-11-15 | 2019-03-12 | 江南大学 | A kind of genetic engineering bacterium producing D-pantoyl lactone hydrolase and its construction method and application |
CN110423717B (en) * | 2019-05-05 | 2021-06-22 | 杭州鑫富科技有限公司 | Multienzyme recombinant cell and method for synthesizing D-pantolactone by multienzyme cascade catalysis |
CN110396505A (en) * | 2019-05-05 | 2019-11-01 | 杭州鑫富科技有限公司 | Ketone group pantoic acid lactone reductase and its application |
CN110408604B (en) * | 2019-08-14 | 2020-11-27 | 华东理工大学 | Formate dehydrogenase mutant with improved substrate affinity and coenzyme affinity |
CN115044638A (en) * | 2022-07-21 | 2022-09-13 | 上海奥萝拉医药科技有限公司 | Preparation method of D-pantolactone with high optical selectivity |
-
2020
- 2020-09-29 CN CN202011046308.1A patent/CN113106129A/en not_active Withdrawn
-
2021
- 2021-08-17 CN CN202110942171.6A patent/CN115044594A/en active Pending
- 2021-08-17 CN CN202110940857.1A patent/CN114426977A/en active Pending
- 2021-08-17 CN CN202110941962.7A patent/CN114426978A/en active Pending
- 2021-08-17 CN CN202110942787.3A patent/CN114426979A/en active Pending
- 2021-09-16 CN CN202111084984.2A patent/CN115011623A/en active Pending
- 2021-09-16 CN CN202111087987.1A patent/CN115029364A/en active Pending
- 2021-09-16 CN CN202111087303.8A patent/CN114774446A/en active Pending
- 2021-09-16 CN CN202111085127.4A patent/CN115011624A/en active Pending
- 2021-09-27 CN CN202111135111.XA patent/CN114457130A/en not_active Withdrawn
- 2021-09-27 CN CN202111133610.5A patent/CN114457128A/en not_active Withdrawn
- 2021-09-27 CN CN202111135083.1A patent/CN114457129A/en not_active Withdrawn
- 2021-09-27 CN CN202111132818.5A patent/CN114457127A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN115011624A (en) | 2022-09-06 |
CN115044594A (en) | 2022-09-13 |
CN114457127A (en) | 2022-05-10 |
CN113106129A (en) | 2021-07-13 |
CN114426979A (en) | 2022-05-03 |
CN114774446A (en) | 2022-07-22 |
CN115029364A (en) | 2022-09-09 |
CN114457130A (en) | 2022-05-10 |
CN114426977A (en) | 2022-05-03 |
CN114457129A (en) | 2022-05-10 |
CN114426978A (en) | 2022-05-03 |
CN114457128A (en) | 2022-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105274070A (en) | Mutant of 7 beta-hydroxyl steroid dehydrogenase, application of mutant and synthesis method | |
CN109735553B (en) | Preparation method of anti-AIDS drug atazanavir intermediate | |
CN106367465A (en) | Method for producing artificial bear gall powder through engineering bacteria fermentation | |
CN114015712A (en) | Preparation method of ursodeoxycholic acid | |
CN114874964A (en) | Construction method and application of recombinant escherichia coli for high yield of 2' -fucosyllactose | |
CN114107152B (en) | Construction method and application of high-yield 3-fucosyllactose microorganism | |
CN115011623A (en) | Recombinant engineering bacterium and construction method and application thereof | |
CN113355367B (en) | Application of ketoacid reductase in synthesis of chiral aromatic 2-hydroxy acid | |
CN109706189B (en) | Preparation method of D-chiro-inositol | |
CN113621590A (en) | Preparation method of S-nicotine | |
CN109679978B (en) | Recombinant co-expression system for preparing L-2-aminobutyric acid and application thereof | |
CN109943542A (en) | A kind of alcohol dehydrogenase for the production of atazanavir intermediate | |
CN109943577A (en) | A kind of bioconversion method of anti-AIDS drug atazanavir intermediate | |
CN104846025B (en) | A kind of method for preparing (2S, 3R) -2- benzoyl aminomethyls -3-hydroxybutyrate methyl esters | |
CN110857444A (en) | Preparation method of scyllo-inositol | |
CN111690696B (en) | Method for preparing darunavir intermediate through biocatalysis | |
CN114085820A (en) | Ketopantolactone reductase derived from Candida viswanathii | |
CN113913399A (en) | Ketopantolactone reductase derived from Candida maltosa Xu316 | |
CN110396506B (en) | L-pantolactone dehydrogenase derived from Nocardia asteroids and use thereof | |
CN109517778B (en) | Method for producing phenyllactic acid by transforming phenylalanine through whole cells of bacillus subtilis | |
CN111635893A (en) | Ketoreductase and application thereof in production of darunavir intermediate | |
CN111705043A (en) | Ketoreductase mutant with improved catalytic activity and application thereof | |
CN114480315B (en) | Baeyer-Villiger monooxygenase and application thereof in brivaracetam synthesis | |
CN116790569B (en) | Pyruvic acid decarboxylase mutant and application thereof in preparation of alpha-hydroxyketone compound | |
CN114657198B (en) | Recombinant engineering bacterium and application thereof in preparation of panto-compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220906 |